Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. The company was founded in 1907 and is headquartered in Vadodara, India.

Revenue projections:

Revenue projections for APLLTD
Revenue projections for APLLTD

APLLTD is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.

Financial Ratios:

currentRatio 1.695000
forwardPE 20.656687
debtToEquity 24.232000
earningsGrowth -0.120000
revenueGrowth 0.167000
grossMargins 0.718110
operatingMargins 0.114750
trailingEps 30.670000
forwardEps 43.500000

A current ratio of 1.695 for APLLTD implies that the company has ample liquidity to meet its short-term debts. APLLTD's cash reserves and current assets should easily cover these obligations, highlighting its financial stability and ability to manage short-term liabilities.
APLLTD's Forward PE being in a reasonable range suggests the stock is fairly priced based on its earnings. The stock isn't overpriced, leaving room for growth, making it an attractive investment for those seeking opportunities for future value appreciation.
APLLTD's low Debt-to-Equity ratio signals the company is not over-leveraged, meaning it has a conservative approach to debt. This reduces financial risk and indicates a stable financial foundation, providing flexibility and security, which can appeal to investors seeking lower-risk investments.
APLLTD's low earnings and revenue growth suggest that the company's profits may shrink. This trend could indicate underlying financial struggles and pose challenges for APLLTD's future profitability.
APLLTD's negative gross and operating margins highlight that the company is incurring losses, unable to generate profit from production or operations. This could be a sign of rising costs or declining revenues, impacting its financial outlook.
APLLTD's forward EPS surpasses its trailing EPS, reflecting expectations of higher profitability in the current year. This suggests that APLLTD is projected to generate stronger earnings, indicating an optimistic financial outlook compared to the prior year's results.

Price projections:

Price projections for APLLTD
Price projections for APLLTD

Alembic Pharmaceuticals Limited's price projections have steadily risen over time, pointing to increasing optimism about the company's prospects. This upward revision suggests that analysts expect Alembic Pharmaceuticals Limited to continue delivering solid performance in the future.

Insider Transactions:

Insider Transactions for APLLTD
Insider Transactions for APLLTD


11 transactions to buy Alembic Pharmaceuticals Limited took place, with market price at 835.5045443448154 per share.There were no buy transactions recorded during the period under consideration.The current trend of more sells at APLLTD's price levels may signal a potential decline. If this selling pressure continues, it could indicate investor pessimism, leading to more price drops in the future.

Recommendation changes over time:

Recommendations trend for APLLTD
Recommendations trend for APLLTD


The recent buy bias from analysts suggests Alembic Pharmaceuticals Limited is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, Alembic Pharmaceuticals Limited appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.